Skip to main content
Premium Trial:

Request an Annual Quote

OGS Extends Research Collaboration with Pfizer for Another Year

NEW YORK, Dec. 14 – Oxford GlycoSciences has extended for another year a proteomics agreement with Pfizer to discover protein biomarkers and potential drug targets for Alzheimer’s disease and atherosclerosis, OGS said Friday.

Under the terms of the renewed agreement, OGS of Oxford, UK, will continue to use its proteomics technology to identify biomarkers in areas of interest to Pfizer. In exchange, Pfizer will provide additional research funding. 

The deal, which was first penned in 1998, was last extended one year ago. At the time Pfizer also took a small stake in OGS.

Pfizer has also renewed its licenses to the OGS human serum and cerebrospinal fluid expression databases and to PC Rosetta, a data analysis software tool. 

OGS has the right to commercialize any diagnostic products arising from the collaboration.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.